

Research

Kidneeds Grants

Since 1997 Kidneeds has awarded \$2,750,000 in research grants that have helped us learn a great deal about DDD and C3GN, both subtypes of C3G.

New Applications

Due date for 2027 Kidneeds Grant Application – December 31, 2026

Award notification – March 1, 2027

Earliest start date – April 1, 2027

[Grant Application \(/sites/kidneeds.lab.uiowa.edu/files/2026-09/Grant_application_Kidneeds_2026-for-2027.doc\)](/sites/kidneeds.lab.uiowa.edu/files/2026-09/Grant_application_Kidneeds_2026-for-2027.doc).

[Grant Instructions \(/sites/kidneeds.lab.uiowa.edu/files/2024-12/Grant_instructions_Kidneeds.doc\)](/sites/kidneeds.lab.uiowa.edu/files/2024-12/Grant_instructions_Kidneeds.doc).

Prior Kidneeds Grants

Grants funded for 2026

1. Sophie Chauvet, M.D., Ph.D.: European Georges Pompidou Hopital, Paris, France
Title: Impact of complement activation on intra renal non-immune cells.

Grants funded for 2024

1. Russel Whelan, M.D., Ph.D.: University of Colorado Anschutz Medical Campus
Title: The roles of CFHR-endothelial interactions in C3G.
2. Veronique Fremeaux-Bacchi, M.D., Ph.D.: European Georges Pompidou Hopital, Paris, France
Title: Molecular mechanisms and therapeutic control of the autoantibodies targeting the alternative pathway C3 convertase.

Grants funded for 2023

1. Kevin Marchbank, Ph.D.: Newcastle University, Newcastle-upon-Tyne, UK
Title: Evaluation of HDM-FH gene therapy in pre-clinical models.
2. Roberta Donadelli, Ph.D.: Mario Negri Institute for Pharmacological Research, Bergamo, Italy
Title: The molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and their impact on treatment.
3. Sophie Chauvet, M.D., Ph.D.: European Georges Pompidou Hospital, Paris, France
Title: Immune signature of C3/C5 convertases activation in C3G.
4. Mihaly Jozsi, Ph.D.: Dept. of Immunology, Pazmany Peter setany 1c, Budapest, Hungary
Title: Modulation of complement convertase enzymes.

Grants funded for 2022

1. Leenert Trouw, Ph.D.: Dept. of Immunology Leiden, The Netherlands
Title: Generating tools to study anti factor H autoantibodies in C3 Glomerulopathy.
2. Diane Karpman, MD. Ph.D.: Dept. of Pediatrics, Clinical Sciences, Lund, Sweden
Title: Renin inhibition as a novel treatment for C3 Glomerulopathy.

Grants funded for 2021

1. Mihaly Jozsi, Ph.D.:
Title: Regulation of Complement Convertases (competitive renewal)

Grants funded for 2020

1. Peter Zipfel, Ph.D.: Jena, Germany

Title: Role of FHR's in C3G Focusing on FHR 1 and FHR 2

2. Mihaly Jozsi, Ph.D.:

Title: Regulation of Complement Convertases

3. Rosella Piras, Ph.D.: Mario Negri Institute, Bergamo, Italy

Title: Understanding the pathogenic role of genomic and molecular FH-FHR abnormalities in DDD and C3G.

4. Sophie Chavet, Ph.D.: Paris France

Title: Impact of immunoglobulin properties in the molecular signature of convertase overactivation in acquired C3G

C3G Scientific Conferences

Kidneeds has also organized multiple international scientific conferences focused on C3G and together with the Molecular Otolaryngology and Renal Research Laboratories (MORL) hosts an annual C3G Family Meeting.

1) The 1st international conference on DDD was held in Boston, MA August 13-14, 2004. The following year, Kidneeds-funded scientists formed the DDD Collaboratory, a virtual center of excellence for DDD research and the only one of its kind in the world devoted to DDD. Six internationally recognized scientists joined the DDD Collaboratory and through this virtual center, they worked together to advance our knowledge of DDD.

2) The 2nd DDD Focus Group Meeting was held August, 2006, as a Hinxtion Retreat in Cambridge, England. Hinxtion Retreats are invitation-only meetings of exceptionally high quality. The 2nd DDD Focus Group Meeting was designated a Conference of Excellence and was sponsored in part by the Wellcome Trust, UK, the NIDDK-NIH, and the Milagros Research Fund. At the conference, scientists recommended adopting the disease name to DDD instead of using the name MPGN Type 2, which does not adequately describe the disease.

3) The 3rd DDD Focus Group Meeting was held August 15-17, 2008, again as a Hinxton Retreat. This Focus Group Meeting was also designated a Conference of Excellence and was sponsored by the Wellcome Trust, UK, the Milagros Research Fund, the NIDDK and the NIH Office of Rare Diseases (ORD).

4) The 4th DDD Focus Group Meeting was held on August 20, 2011 in Leiden, The Netherlands, immediately before the 13th European Meeting on Complement in Human Disease.

5) The 5th C3G (C3GN/DDD) Focus Group Meeting was held on June 26, 2015 in Uppsala, Sweden immediately before the 15th European Meeting on Complement in Human Disease. It was the largest Focus Group Meeting to date. The name C3G (for C3 Glomerulopathy) was adopted, reflecting advances in our understanding of DDD and a similar disease, C3 Glomerulonephritis (C3GN), both now classified as subtypes of C3G.

6) The 6th C3G Focus Group Meeting was held on September 8, 2017 in Copenhagen, Denmark as a satellite meeting immediately before the 16th European Meeting on Complement in Human Disease and resulted in the following publication: Smith et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review. PubMed PMID: 30692664.

7) The 7th C3G Focus Group Meeting was held on September 14, 2019 in Madrid, Spain in conjunction with the 17th European Meeting on Complement in Human Disease.

IOWA

Kidneeds

Iowa City, Iowa 52242

☎ [319-335-3500](tel:319-335-3500)

© 2026 The University of Iowa